The heterozygous TNNT1 p.(Asp65Ala) variant is likely pathogenic for autosomal dominant nemaline myopathy, causing muscle weakness and altered troponin-tropomyosin interactions.
Answers are grounded in this paper and cite their sources.
May prompt TNNT1 testing in dominant NEM families; leaves open causality confirmation and prevalence estimates.
Nemaline myopathies (NEMs) are genetically and clinically heterogenous. Biallelic or monoallelic variants in TNNT1, encoding slow skeletal troponin T1 (TnT1), cause NEM. We report a 2-year-old patient and his mother carrying the heterozygous TNNT1 variant c.194A>C/p.(Asp65Ala) that occurred de novo in the mother. Both had muscle hypotrophy and muscle weakness. Muscle pathology in the proband's mother revealed slow twitch type 1 fiber hypotrophy and fast twitch type 2 fiber hypertrophy that was confirmed by a reduced ratio of slow skeletal myosin to fast skeletal myosin type 2a. Reverse transcription polymerase chain reaction and immunoblotting data demonstrated increased levels of high-molecular-weight TnT1 isoforms in skeletal muscle of the proband's mother that were also observed in some controls. In an overexpression system, complex formation of TnT1-D65A with tropomyosin 3 (TPM3) was enhanced. The previously reported TnT1-E104V and TnT1-L96P mutants showed reduced or no co-immunoprecipitation with TPM3. Our studies support pathogenicity of the TNNT1 p.(Asp65Ala) variant.
No takes yet. Share an insight, caveat, or question.
Holling et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: